Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 2
2010 1
2011 6
2012 5
2013 1
2014 5
2015 8
2016 6
2017 8
2018 6
2019 9
2020 5
2021 6
2022 3
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

68 results

Results by year

Filters applied: . Clear all
Page 1
Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial.
Mankikian J, Caille A, Reynaud-Gaubert M, Agier MS, Bermudez J, Bonniaud P, Borie R, Brillet PY, Cadranel J, Court-Fortune I, Crestani B, Debray MP, Gomez E, Gondouin A, Hirschi-Santelmo S, Israel-Biet D, Jouneau S, Juvin K, Leger J, Kerjouan M, Marquette CH, Naccache JM, Nunes H, Plantier L, Prevot G, Quetant S, Traclet J, Valentin V, Uzunhan Y, Wémeau-Stervinou L, Bejan-Angoulvant T, Cottin V, Marchand-Adam S; EVER-ILD investigators and the OrphaLung network. Mankikian J, et al. Among authors: bejan angoulvant t. Eur Respir J. 2023 Jun 8;61(6):2202071. doi: 10.1183/13993003.02071-2022. Print 2023 Jun. Eur Respir J. 2023. PMID: 37230499 Free article. Clinical Trial.
Information et communication sur les risques liés au médicament et son bon usage auprès des professionnels de santé et du public : principe de précaution, gestion du risque, communication pendant et en dehors des situations de crise.
Molimard M, Bernaud C, Lechat P; et les participants à la table ronde N°6 de Giens XXIX :; Bejan-Angoulvant T, Benattia C, Benkritly A, Braunstein D, Cabut S, David N, Fourrier-Réglat A, Gallet B, Gersberg M, Goni S, Jolliet P, Lamarque-Garnier V, Le Jeunne C, Leurs I, Liard F, Malbezin M, Micallef J, Nguon M. Molimard M, et al. Among authors: bejan angoulvant t. Therapie. 2014 Jul-Aug;69(4):355-60. doi: 10.2515/therapie/2014044. Therapie. 2014. PMID: 27393228 French. No abstract available.
[Endogenous and exogenous estrogens].
Bejan-Angoulvant T, Arnal JF. Bejan-Angoulvant T, et al. Presse Med. 2019 Nov;48(11 Pt 1):1244-1248. doi: 10.1016/j.lpm.2019.10.008. Epub 2019 Nov 12. Presse Med. 2019. PMID: 31732361 Review. French.
False positive results in preclinical research.
Angoulvant D, Bejan-Angoulvant T. Angoulvant D, et al. Among authors: bejan angoulvant t. Therapie. 2017 Sep;72(4):411-413. doi: 10.1016/j.therap.2016.06.001. Epub 2016 Jun 22. Therapie. 2017. PMID: 27567552 No abstract available.
The best in coronary artery disease management is yet to come.
Angoulvant D, Bejan-Angoulvant T. Angoulvant D, et al. Among authors: bejan angoulvant t. Arch Cardiovasc Dis. 2018 Nov;111(11):621-624. doi: 10.1016/j.acvd.2018.10.001. Epub 2018 Oct 23. Arch Cardiovasc Dis. 2018. PMID: 30366857 Free article. No abstract available.
68 results